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Abstract
Purpose: Both concurrent and sequential chemoradiotherapy have been reportedto be good alternatives to total laryngectomy in patients with locally advancedhypopharyngeal cancer. We retrospectively reviewed the results of concurrent vssequential chemoradiotherapy in two institutions for treatment of locally advancedresectable hypopharyngeal cancer in an effort to optimize future laryngealpreservation treatment. Methods: Seventy-two patients with locally advancedresectable hypopharyngeal squamous cell carcinoma were reviewed. Arm Iincluded 38 patients treated by concurrent chemoradiotherapy (CCRT) while armII included 34 patients received sequential chemoradiotherapy. In arm I patientsreceived CCRT of cisplatin 100 mg/m2d1, 22 of radiotherapy at dose of 65 Gy/1.8 -2 Gy/f, 5 days/week. Patients in arm II received 2 cycles of inductionchemotherapy consisted of 5 - fluorouracil 1000 mg/m2 on d1 - 4 on 24 hcontinuous infusion plus cisplatin 100 mg/m2 d1; cycle was repeated every 3weeks followed by radiotherapy as in arm I. Results: Demographic data werebalanced in both arms. The median age was 50 and 48 years in arm I and IIrespectively. There was male predominance in both arms. Most of the patientswere of ECOGPS of 1and of stage III. No recorded deaths due to treatment toxicities.But as expected CCRT was associated with higher toxicity. In order of frequency;mucositis, anemia were higher in arm I. Significantly higher response rate wasobserved in arm I (p = 0.04).Three-year survival rates were 74% in arm I and67.9% in arm II with no significant difference (p = 0.074) but 3 - year PFS rate wassignificantly higher in arm I (52.6% vs. 47%) (p = 0.03). Laryngeal - preservationrate was 78% in arm I vs. 56% in arm II with significant difference. Conclusion:There was higher benefit of concurrent chemo-radiotherapy over sequentialchemoradiotherapy. However, larger number of patients and prospectiverandomized trials are needed to confirm our findings. New strategies that improveorgan preservation with less toxicity are needed.
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1. IntroductionCancer of hypopharynx is uncommon; approximately2,500 new cases are diagnosed each year in the UnitedStates.1 Locally advanced resectable tumors ofhypopharynx may be treated with surgery followed byradiation, sequential or concomitant chemoradiation. Inthese cases, surgery involves total laryngectomy, partialor total pharyngectomy with neck dissection. Inspite ofthis radical surgery, there is consequent functionalimpairment and poor prognosis . Conventionalfractionated radiotherapy (RT) up to total dose of 66 -
70 Gy over 7 weeks has been used as definitivetreatment for locally advanced tumors instead ofsurgery. Unfortunately this results in high locoregionalrelapse (50 - 60% at 2 - years) and overall survival ofabout 40% at 3 years.2, 3 For this combined modalitytherapy has focused on the dual goals of increasedsurvival and functional organ preservation; but it hasdisadvantage of absence of precise pathologic stagingand identification of high risk features that influenceprognosis.
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Advantages of induction chemotherapy (IC) followed bydefinitive radiotherapy (RT) include:1) the potential todecrease the risk of distant failure; 2) rapid reduction intumor bulk. Nonetheless, this can result in prolongedtreatment and additional chemotherapy - relatedtoxicity from systemic doses.4 Theoretical benefits ofdelivering concurrent chemoradiotherapy (CCRT) are:1) radiosensitization of antitumor activity of RT bysimultaneous use of chemotherapy; 2) systemic use ofchemotherapy may improve survival and eradicatemicrometastases outside the irradiated field.The aim of this study was to review the experience withCCRT versus IC followed by definitive RT (sequentialchemoradiotherapy) for treatment of locally advancedresectable hypopharyngeal cancer in an effort tooptimize future laryngeal preservation treatment.
2. Methods and Materials
2.1. Study populationSeventy - two consecutive patients treated betweenJanuary 2000 and December 2010 at two institutionswere included in this retrospective study. All patientshad stage III - IVA resectable hypopharyngeal squamouscell carcinoma (SCC) according to criteria of theAmerican Joint Committee on cancer 2002.5 Pre -treatment evaluation included physical examination,panendoscopy and biopsy, computed tomography (CT)or magnetic resonance imaging (MRI) of neck and chestand routine laboratory studies.Other eligibility criteria were: Eastern CooperativeOncology Group performance status ECOGPS of 0 - 2, ageyounger than 70 years, adequate hematological, renaland hepatic functions tests and patients treated by CCRT(arm I) or sequential chemoradiotherapy (arm II).
2.2. Treatment planPatients in arm I (38 patients) received CCRT consistedof cisplatin 100 mg/m2 d1 and 22 concurrent with RT.Radiotherapy was given 5 days a week withconventional RT at 1.8 - 2 Gy/day to total dose of 65 Gyto the primary site and gross lymphadenopathy but to50 Gy to N0 with cord off after 45 Gy. Cobalt 60 or 6-MVlinear accelerator was used for RT sessions.Patients in arm II (34 patients) were treated by ICconsisted of 5 – fluorouracil (5 - FU) 1000 mg/m2 ondays 1 - 4 and cisplatin 100 mg/m2d1 repeated every 3weeks. Adequate hydration and antiemetics were givenbefore chemotherapy. After 2 cycles of IC, patientsreceived RT sessions as in arm I.
2.3. Assessment of treatmentToxic effects were graded according to the NationalCancer Institute Common Toxicity Criteria, version 3.0,6while response evaluation was based on the RECISTcriteria.7 Response was assessed through clinicalexamination, endoscopy and CT or MRI.Patients were followed - up after completion oftreatment at monthly intervals for first year and every 3months for second year then at 6-months intervalsthereafter.Overall survival (OAS) rate was defined as the durationbetween the date of treatment initiation and that of lastfollow - up or death while disease - free survival (DFS)was defined as the duration between date of initiation oftreatment and that of disease progression. Laryngeal –preservation rate was calculated from date of starttreatment to date of laryngectomy.
2.4. Statistical methods: Data was analysed by usingSPSS (version 15.0), Chi square test used as a test ofsignificance, Kaplan – Meier test was used for survivalfunction (OAS, PFS), and comparison of curves was doneby using Log Rank. A p value ˂ 0.05 is statisticallysignificant.
3. ResultsWe identified 72 patients met the eligibility criteria outof them 38 patients received CCRT (arm I) and 34received sequential treatment (arm II). Demographicdata were balanced in both arms (Table1). The medianage was 50 and 48 years in arm I and II respectively.There was male predominance in both arms. Most of thepatients were of ECOGPS of 1 and of stage III.No deaths were recorded due to treatment toxicities.However, as expected CCRT was associated with highertoxicity (Table 2). In order of frequency; mucositis,anemia and tube feeding were higher in arm I (28.9, 18.4and 15.8%, respectively).As shown in Table 3; significantly higher response ratewas observed in arm I (p = 0.04). Three - year survivalrates were 74 in arm I and 67.6 in arm II with nosignificant difference (Figure 1) (p = 0.074) but 3 - yearPFS rate was significantly higher in arm I (52.6 vs. 47) (p= 0.03) (Figure 2). Laryngeal - preservation rate was78% in arm I vs. 56% in arm II, with significantdifference (p = 0.036).
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Table 1: Patients demographicsVariable Arm I (38) Arm II (34) PN % N %Age, yearsMedian 50 48Range 35-74 33-73Sex Male 35 92.1 32 94.1 1Female 3 7.9 2 5.9 1ECOGPS 0 13 34.2 10 29.4 0.801 19 50 19 55.9 0.452 6 15.8 5 14.7 1Stage III 26 68.4 21 61.8 0.62IVA 12 31.6 13 38.2 0.62
Table 2: Grade 3-4 acute toxic effectsToxic effects Arm I Arm IIN % N %Neutropenia 5 13.2 4 11.8Thrombocytopenia 3 7.9 2 5.9Anemia 7 18.4 3 8.8Nausea/vomiting 5 13.2 5 14.7Mucositis 11 28.9 6 17.6Tube feeding 6 15.8 2 5.9Tracheostomy 2 5.3 2 5.9Xerostomia 3 7.9 2 5.9

















Figure 1: Over All Survival (OAS) among studied cases
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Figure 2: Progression Free Survival (PFS) among studied cases
4. DiscussionOver the last two decades, larynx preservation has beenconsidered one of the most important aims in head andneck oncology. The rationale for CCRT is based onexperimental evidence of synergism betweenchemotherapy and radiation. Theoretically this ismediated by interference with multiple intracellularradiation – induced stress - response pathways involvedin apoptosis, proliferation and DNA repair.8 However;increased toxic effects with CCRT remain majorconcerns in organ preservation.9, 10 Cisplatin has theadvantage of not having mucositis as toxicity; althoughas a radiation sensitizer it does increase radiation -induced mucositis. This can explain the higher incidenceof mucositis in CCRT arm (28.9 vs 17.6%). Also,increased mucositis lead to higher need for tube feedingand increased anemia due to nutritional deficiency inCCRT. Although the high toxicity rates in CCRT, therewas no reported deaths due to complications oftreatment.Advances in diagnostic imaging have contributed inimprovement in radiation therapy planning. Both PETand MRI allow better tumor delineation and allow theoncologist to more accurately outline the tumor.11, 12, 13Intensity - modulated radiotherapy techniques enablesthe reduction of dose to normal structures whileincreasing it to the tumor lead to decreasing toxicity.There was significantly higher response rate in CCRTarm that was comparable to previous studies.14, 15, 16 Inour study, laryngeal – preservation and PFS rates weresignificantly higher with CCRT (P = .036, .03,respectively), co - incided with that reported byForastiere et al.17 and Parades et al.18A meta - analysisconfirmed the overall survival benefit of CCRT.19, 20However; in the present study this benefit did not reachstatistically significant value.
Trial data have shown TPF (taxotere, platinol, 5-FU)more effective than PF in larynx preservation and haveconsidered it the preferred induction chemotherapy inthis setting.21, 22 Post induction radiotherapy and atargeted agent as epidermal growth receptor inhibitorcetuximab, instead of cisplatin, may help to improveoverall tolerability of treatment while retaining activity.
23
5. ConclusionThere was higher benefit of concurrentchemoradiotherapy over sequential chemoradiotherapy.However, larger number of patients and prospectiverandomized trials are needed to confirm our findings.New strategies that improve organ preservation withless toxicity are also needed.
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